Literature DB >> 7584106

Suppression of various human tumor cell lines by a dominant negative H-ras mutant.

Y Ogiso1, N Sakai, H Watari, T Yokoyama, N Kuzumaki.   

Abstract

A dominant negative H-ras mutant, N116Y, was transfected into a variety of human tumor cell lines. N116Y extremely inhibited the proliferation of A431 (vulva), PC3 (prostate), T24 (bladder), MCF7 (breast), NKPS and TMK1 (stomach) cancer cell lines. A431 and PC3 cells were particularly susceptible to N116Y. In order to examine the effects of N116Y on the neoplastic phenotypes, we transfected a less efficient N116Y expression vector into A431 cells. Almost all clones survived after G418 selection. However, they did not retain the N116Y gene and only one clone faintly expressed N116Y. This N116Y-expressing clone had no tumorigenicity in vivo, and revealed deformed morphology and DNA fragmentation, suggesting that N116Y might have induced apoptotic cell death. Thus, N116Y may be applicable for gene therapy of a wide spectrum of human tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584106

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  3 in total

1.  Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.

Authors:  P L de Souza; M Castillo; C E Myers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 2.  Gene therapy for carcinoma of the breast: Genetic toxins.

Authors:  G Vassaux; N R Lemoine
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

3.  Noninvasive Imaging of Ras Activity by Monomolecular Biosensor Based on Split-Luciferase Complementary Assay.

Authors:  Liang Chen; Wei Bing Leng; De Zhi Li; Hong Wei Xia; Min Ren; Qiu Lin Tang; Qi Yong Gong; Fa Bao Gao; Feng Bi
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.